- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05638295
KRAS G12C 돌연변이 고형암에 대한 표적 치료제로서 AMG 510(소토라십) 및 파니투무맙의 사용 테스트(ComboMATCH 치료 시험)
진행성 고형 종양에서 Panitumumab을 포함하거나 포함하지 않는 AMG 510(Sotorasib)의 무작위 2상 연구: ComboMATCH 치료 시험
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
연구 개요
상태
상세 설명
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, 미국, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
California
-
Los Angeles, California, 미국, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, 미국, 90025
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Palo Alto, California, 미국, 94304
- VA Palo Alto Health Care System
-
-
Florida
-
Aventura, Florida, 미국, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, 미국, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, 미국, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, 미국, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Hollywood, Florida, 미국, 33021
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Jacksonville, Florida, 미국, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, 미국, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, 미국, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, 미국, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, 미국, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, 미국, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, 미국, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, 미국, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, 미국, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, 미국, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, 미국, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, 미국, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, 미국, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, 미국, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, 미국, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, 미국, 60612
- University of Illinois
-
Chicago, Illinois, 미국, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, 미국, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, 미국, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, 미국, 61832
- Carle at The Riverfront
-
Decatur, Illinois, 미국, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, 미국, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, 미국, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, 미국, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, 미국, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, 미국, 60123
- Advocate Sherman Hospital
-
Hazel Crest, Illinois, 미국, 60429
- Advocate South Suburban Hospital
-
Libertyville, Illinois, 미국, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, 미국, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, 미국, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, 미국, 60153
- Loyola University Medical Center
-
Normal, Illinois, 미국, 61761
- Carle Cancer Institute Normal
-
Normal, Illinois, 미국, 61761
- Carle BroMenn Medical Center
-
O'Fallon, Illinois, 미국, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, 미국, 60453-2699
- Advocate Christ Medical Center
-
Oak Lawn, Illinois, 미국, 60453
- Advocate Outpatient Center - Oak Lawn
-
Palos Heights, Illinois, 미국, 60463
- Advocate High Tech Medical Park
-
Park Ridge, Illinois, 미국, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, 미국, 62269
- Memorial Hospital East
-
Springfield, Illinois, 미국, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, 미국, 62702
- Springfield Clinic
-
Springfield, Illinois, 미국, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, 미국, 61801
- Carle Cancer Center
-
-
Iowa
-
Ankeny, Iowa, 미국, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, 미국, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, 미국, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, 미국, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, 미국, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, 미국, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, 미국, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, 미국, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, 미국, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, 미국, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, 미국, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, 미국, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, 미국, 48118
- Chelsea Hospital
-
Dearborn, Michigan, 미국, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, 미국, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, 미국, 48503
- Hurley Medical Center
-
Flint, Michigan, 미국, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, 미국, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, 미국, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, 미국, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, 미국, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, 미국, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, 미국, 48073
- Corewell Health William Beaumont University Hospital
-
Royal Oak, Michigan, 미국, 48073
- Corewell Health Children's
-
Saginaw, Michigan, 미국, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, 미국, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, 미국, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, 미국, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, 미국, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, 미국, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, 미국, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Deer River, Minnesota, 미국, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, 미국, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, 미국, 55746
- Essentia Health Hibbing Clinic
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, 미국, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, 미국, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, 미국, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, 미국, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, 미국, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, 미국, 63110
- Washington University School of Medicine
-
St Louis, Missouri, 미국, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, 미국, 63136
- Siteman Cancer Center at Christian Hospital
-
-
Montana
-
Anaconda, Montana, 미국, 59711
- Community Hospital of Anaconda
-
Billings, Montana, 미국, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, 미국, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, 미국, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, 미국, 59901
- Logan Health Medical Center
-
Missoula, Montana, 미국, 59804
- Community Medical Center
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, 미국, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, 미국, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, 미국, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, 미국, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, 미국, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Columbus, Ohio, 미국, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, 미국, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, 미국, 43228
- Doctors Hospital
-
Columbus, Ohio, 미국, 43215
- Grant Medical Center
-
Dayton, Ohio, 미국, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, 미국, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, 미국, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, 미국, 43016
- Dublin Methodist Hospital
-
Dublin, Ohio, 미국, 43016
- Columbus Oncology and Hematology Associates
-
Kettering, Ohio, 미국, 45429
- Kettering Medical Center
-
Mansfield, Ohio, 미국, 44903
- OhioHealth Mansfield Hospital
-
Marion, Ohio, 미국, 43302
- OhioHealth Marion General Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, 미국, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, 미국, 97213
- Providence Portland Medical Center
-
Portland, Oregon, 미국, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- Thomas Jefferson University Hospital
-
Willow Grove, Pennsylvania, 미국, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, 미국, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, 미국, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, 미국, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, 미국, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, 미국, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, 미국, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, 미국, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, 미국, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, 미국, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, 미국, 37604
- Regional Cancer Center at Johnson City Medical Center
-
Kingsport, Tennessee, 미국, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, 미국, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Nashville, Tennessee, 미국, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Temple, Texas, 미국, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Bristol, Virginia, 미국, 24201
- Ballad Health Cancer Care - Bristol
-
Charlottesville, Virginia, 미국, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, 미국, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, 미국, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, 미국, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Charleston, West Virginia, 미국, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Appleton, Wisconsin, 미국, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, 미국, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, 미국, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, 미국, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, 미국, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, 미국, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, 미국, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, 미국, 54311
- Aurora BayCare Medical Center
-
Janesville, Wisconsin, 미국, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kenosha, Wisconsin, 미국, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, 미국, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, 미국, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, 미국, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, 미국, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, 미국, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, 미국, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, 미국, 54956
- ThedaCare Regional Medical Center - Neenah
-
New London, Wisconsin, 미국, 54961
- ThedaCare Cancer Care - New London
-
Oshkosh, Wisconsin, 미국, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, 미국, 54904
- ThedaCare Cancer Care - Oshkosh
-
Racine, Wisconsin, 미국, 53406
- Aurora Cancer Care-Racine
-
Shawano, Wisconsin, 미국, 54166
- ThedaCare Cancer Care - Shawano
-
Sheboygan, Wisconsin, 미국, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, 미국, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, 미국, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waupaca, Wisconsin, 미국, 54981
- ThedaCare Cancer Care - Waupaca
-
Wauwatosa, Wisconsin, 미국, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, 미국, 53227
- Aurora West Allis Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
-
Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
-
Patient must be >= 18 years of age
-
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
-
Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
-
Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
-
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)
-
Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization
-
Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible
-
Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption
-
Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis
-
Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition
-
Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab
-
Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)
-
Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)
-
COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
-
COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
-
COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
- NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
-
COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
다른 이름들:
Undergo collection of blood
다른 이름들:
Undergo CT scan
다른 이름들:
Undergo tumor biopsy
다른 이름들:
Given IV
다른 이름들:
Given PO
다른 이름들:
|
|
활성 비교기: Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
다른 이름들:
Undergo collection of blood
다른 이름들:
Undergo CT scan
다른 이름들:
Undergo tumor biopsy
다른 이름들:
Given PO
다른 이름들:
|
|
실험적: Cohort II (sotorasib, panitumumab)
Patients receive combination therapy as in Arm A. |
Undergo MRI
다른 이름들:
Undergo collection of blood
다른 이름들:
Undergo CT scan
다른 이름들:
Undergo tumor biopsy
다른 이름들:
Given IV
다른 이름들:
Given PO
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS) (Cohort I)
기간: From registration to documented disease progression or death from any cause, assessed up to 3 years
|
PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level. |
From registration to documented disease progression or death from any cause, assessed up to 3 years
|
|
Best objective response (Cohort II)
기간: From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors. |
From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
|
Overall response rate (ORR) (Cohort II)
기간: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used. |
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival (OS) (Cohort I)
기간: Up to 3 years
|
OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported. |
Up to 3 years
|
|
ORR (Cohort I)
기간: Up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
Up to 3 years
|
|
Disease control rates (Cohort I)
기간: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
PFS (Cohort II)
기간: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
|
OS (Cohort II)
기간: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Kristen R Spencer, ECOG-ACRIN Cancer Research Group
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NCI-2022-09876
- U10CA180820 (미국 NIH 보조금/계약)
- NCI-2022-09876 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- EAY191-E5 (기타 식별자: CTEP)
- EAY191-E5 (기타 식별자: ECOG-ACRIN Cancer Research Group)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .